Karachi: BF Biosciences Limited has announced that its Board of Directors will convene on February 27, 2025, through a video link at 17:00 to review the company’s quarterly accounts for the period ending December 31, 2024. This meeting will also consider the declaration of any entitlement based on the reviewed accounts.

In preparation for the board meeting, the company has instituted a closed period starting February 20, 2025, and concluding on February 27, 2025. During this time frame, directors, the CEO, and executives are prohibited from engaging in any direct or indirect transactions involving the company's shares. This measure is in compliance with section 5.6.1(d) of the Pakistan Stock Exchange (PSX) regulations.

According to information available from the Pakistan Stock Exchange (PSX), BF Biosciences Limited has communicated the necessary details to the TRE Certificate Holders of the exchange to ensure transparency and adherence to regulatory requirements. The designated market category for the company remains consistent with its sector classification.